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Background: Previous studies revealed a high incidence of late-onset Fabry disease mutation, IVS4 + 919GNA, in
Taiwan. However, the natural course is largely unclear and suitable biomarkers for monitoring disease progress
are unavailable.
Methods and results: Patients carrying IVS4 + 919GNA or classical Fabry mutations were enrolled in this study.
The subjects ranged from newborn to eighty year old adults. Plasma globotriaosylceramide (Gb3) and
globotriaosylsphingosine (lysoGb3) were measured by LC-MS/MS in subjects to evaluate the sensitivity of
these two biomarkers. All adult males and symptomatic females could be distinguished from healthy controls
by an elevated plasma lysoGb3 level. The lysoGb3 level was also related to the left ventricular mass considering
gender and age (p b 0.01). Moreover, approximately 70% of male and 45% of female newborns already had an el-
evated plasma lysoGb3 level which increased gradually as the subjects got older (p b 0.01).
Conclusions: Plasma lysoGb3 is a more sensitive and reliable biomarker than plasma Gb3. LysoGb3 also
correlated with age and left ventricular mass index in Fabry patients with IVS4 + 919GNA mutation. Be-
cause lots of infants with the IVS4 + 919GNA mutation already had elevated lysoGb3 levels at birth, that
indicates that the development of hypertrophic cardiomyopathy may require a long and insidious course
after lysoGb3 accumulation.© 2013 Elsevier B.V. Open access under CC BY license.globotriaosylsphingosine; LVMI, left ventricular mass index; LC-MS/MS, high performance liquid chromatography mass spec-
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Fabry disease (MIM 301500) is a panethnic, X-linked, inborn
error of glycosphingolipid metabolism resulting from mutations in
the α‐galactosidase A gene leading to deﬁcient activity of a lysosom-
al enzyme, α‐galactosidase A (GLA, EC 3.2.1.22) [1,2]. Deﬁciency of
this enzyme, α‐galactosidase A, which is involved in the metabolic
breakdown of globotriaosylceramide (Gb3) results in progressive
accumulation of Gb3 and related glycosphingolipids in lysosomes
of all cells in the body. Affected male patients who have little or no
GLA activity exhibit the classic phenotype of Fabry disease, presenting
acroparesthesias, angiokeratomas, hypohidrosis in early childhood or
adolescence [3], progressing to renal insufﬁciency, cardiomyopathy, and
cerebrovascular disease in adulthood. Awide spectrum of phenotypic ex-
pression found in heterozygous females is considered generally as effects
of random inactivation of X-chromosome during embryogenesis. Despite
the wide range of disease severity, several heterozygous females still de-
velop vital organ damages and lead to severe morbidity and mortality
[4–6]. Over the past decades, different atypical types of Fabry disease
have been identiﬁed [7,8], which have drawn the attention of more phy-
sicians. Patients with atypical Fabry disease have higher residual enzyme
activities than those of the classical type. They lack the classic symptoms
of Fabry disease and present relatively fewer or isolated symptoms such
as hypertrophic cardiomyopathy, renal failure, or cryptogenic stroke at
later stages in life [7–10]. The estimated incidence of classic Fabry disease
is 1 in 40,000–60,000males in the general population [11]. Previous stud-
ies of Fabry newborn screening, however, revealed a remarkably higher
prevalence of about 1:900 to 1:4000 in males and 1:400 to 1:2000 in fe-
males for atypical Fabry disease [12–15]. These ﬁndings indicated that
the atypical Fabry disease might represent a major neglected public
health problem in at least some ethnic groups. However, the natural
course of atypical Fabry diseases is still unclear, and suitable biomarkers
for monitoring the disease progression have not been established.
Our team ﬁrst discovered a surprisingly high incidence (≈1 in 1600
males) of a cardiac variant GLAmutation, IVS4 + 919GNA, in Taiwanese
through newborn screening [16] and further identiﬁed this mutation in
a number of adult patients with idiopathic hypertrophic cardiomyopa-
thy [13]. Thereafter, another newborn screening center in Taiwan also
found a similar incidence (1 in 1460 males) of this mutation in their
study [14]. Higher prevalence rate (72% of males and 35% of females)
of this IVS4 + 919GNA mutation was also detected in over 40 year-
old adults with cardiomyopathy [6]. This mutation not only leads to hy-
pertrophic cardiomyopathy, but can also potentially cause mild impair-
ment of the kidneys and the eyes [17]. Recently, a DNA-based newborn
screening for this mutation revealed a higher incidence of this mutation
(1/875 inmales and 1/399 in females) than our previous enzyme-based
Fabry newborn screening in Taiwan [18]. In addition to Taiwan, this mu-
tation has also been found in Japan [19], Mainland China, Singapore (Han
population), and Malaysia (Han population) by our team (unpublished
data). Therefore, we believe that IVS4 + 919GNA Fabry mutation may
be one of the most common pathogenic mutations of Fabry disease. It is
important to understand the natural course of the disease and determine
the best time to start enzyme replacement therapy (ERT).
Gb3 in plasma or urine has been used as a biomarker to monitor the
clinical course and the response to ERT in Fabry disease. However, these
biomarkers cannot truly reﬂect Fabry disease manifestations and
therapeutic outcomes [20–22]. Furthermore, these biomarkers, espe-
cially plasma Gb3, were not sensitive enough to detect a large pro-
portion of the heterozygous females and atypical variants [23,24].
Recently, Aerts et al. introduced a newmarker for Fabry disease, namely
globotriaosylsphingosine (lysoGb3), which is dramatically increased in
the plasma of classical Fabry patients [25]. Thereafter, plasma lysoGb3
was proven to have a signiﬁcantly higher diagnostic sensitivity com-
pared to plasma Gb3 [24,26,27], especially in heterozygous females
[24,28]. Because a reduction of lysoGb3 levels both in plasma and tissue
was clearly observed upon ERT, plasma lysoGb3 might be a reliablemarker for monitoring the therapeutic outcomes of ERT [26,27]. A diag-
nosticmethod formeasuring urine lysoGb3was recently developed and
showed the close correlation of the urinary excretion of lysoGb3 with
the genotype. That suggested a possible value of lysoGb3 for predicting
clinical severity [29].
More recently, a fast and reliable LC-MS/MS assay was also devel-
oped to analyze plasma lysoGb3 levels [29,30]. Low residual enzyme ac-
tivity is usually related to high plasma lysoGb3 levels [31]. However,
most of these studies were limited to classical Fabry disease; atypical
variants have rarely been analyzed. In our previous study, we found
that almost all adult males (including symptomatic and asymptomatic)
and symptomatic females with the IVS4 + 919GNA mutation can be
distinguished from the normal controls by an elevated plasma lysoGb3
level, but not Gb3, and someof the newbornswith thismutation already
had elevated lyso-Gb3 levels [32,33]. A similar ﬁnding was also ob-
served by another newborn screening center in Taiwan [34]. In this
study, we ﬁrst enrolled subjects with classical or IVS4 + 919GNAmuta-
tion to evaluate the sensitivity of plasma Gb3 and lyso-Gb3 levels in
these individuals. We then further analyzed plasma lysoGb3 levels in
symptomatic and asymptomatic subjects with the IVS4 + 919GNAmu-
tation, and evaluated the relationship between the values of plasma
lysoGb3 and left ventricular mass index (LVMI) in subjects with the
IVS4 + 919GNA mutation. Finally, we evaluated the nature course of
the manifestation of plasma lysoGb3 levels in the subjects carrying the
IVS4 + 919GNA mutation.
2. Materials and methods
2.1. Ethics approval
The study was approved by the institutional review board of Taipei
Veterans General Hospital (No. 2012-02-065B). Written informed con-
sents were obtained from parents of children and from adult subjects
(over 20 years old) before beginning individual examinations.
2.2. Subjects
2.2.1. Evaluating the sensitivity of plasma Gb3 and lysoGb3 levels in the
subjects with a classical or IVS4 + 919GNA mutation
A total of 75 adults (N20 years old, including 32 males and 43
females) carrying the IVS4 + 919GNA mutation and 20 Fabry patients
(including 3 newborns and 17 adults) carrying classical mutations
were enrolled in the ﬁrst part of this study. Plasma Gb3 and lysoGb3
levels were measured to evaluate the sensitivity of these two bio-
markers in these individuals. Except for three infants, all the individuals
with the classical Fabrymutationswere symptomatic patients. All blood
samples in this studywere obtained before the initiation of ERT. Control
samples from 31 healthy adults (16 males and 15 females) were en-
rolled to establish normal reference values of plasma lysoGb3. All indi-
viduals in the normal control group were conﬁrmed to have normal
enzyme activity andwithout carrying any knownmutation in GLA gene.
2.2.2. Evaluation of plasma lysoGb3 levels and the relationship of plasma
lysoGb3 and left ventricular mass index (LVMI) in subjects with a IVS4 +
919GNA mutation
The objective of the second part of this study was to investigate the
relationship between lysoGb3 and clinical manifestation in the adults
(N20 years old) carrying the IVS4 + 919GNA mutation. In this part of
the study, our sample size was extended to 146 individuals and divided
into symptomatic and asymptomatic subjects. Another 72 healthy
adults (35 males and 37 females) were enrolled as normal controls.
The adults carrying the IVS4 + 919GNA mutation without any cardiac
symptoms and signs (such as left ventricular hypertrophy [35], left ven-
tricular diastolic dysfunction, etc.) were deﬁned as asymptomatic
group, while individuals who have already developed cardiac symp-
toms (left ventricular mass index (LVMI) N51 g/m2.7 in males and
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relationship between the values of plasma lysoGb3 and LVMI in both
male and female adults with the IVS4 + 919GNA mutation was also
analyzed.
2.2.3. The relationship of plasma lysoGb3 and age in subjects with the
IVS4 + 919GNA mutation
The objective of the third part of the study is to understand the var-
iation in the manifestation of plasma lysoGb3 in the subjects carrying
the IVS4 + 919GNA mutation at different ages. In this part of the
study, the sample size was enlarged from 146 to 256 individuals (in-
cluding137males and 119 females) carrying the IVS4 + 919GNAmuta-
tion plus 124 healthy subjects (including 61 males and 63 females) as
the normal control group. The age of these subjects in this study ranged
from newborn to eighty years of age to reveal the possible natural
course of lysoGb3. Laboratory technicians were blind to all studied sam-
ples including the normal healthy control group and individuals carrying
the IVS4 + 919GNA mutation. The number and age distributions of nor-
mal healthy controls and enrolled individuals with the IVS4 + 919GNA
mutation or classical mutations are listed in Table 1.
2.3. Methods
2.3.1. Sample preparation for plasma lysoGb3 and Gb3
Calibration standards or 50 μL of plasma samples, and internal stan-
dardwere added to a 96well plate. The lipidswere extracted for 10 min
with 800 μL of chloroform/methanol 2:1 (v/v), then centrifuged for
10 min at 4000 rpm. Without disturbing the pellet at the bottom of
the well, 600 μL supernatant was transferred using a liquid handler
(TECAN Freedom EVO, Austria) to a new plate containing 150 μL with
1% formic acid in each well. After extraction for 10 min, the samples
were centrifuged again. The 200 μL of aqueous phase (water and meth-
anol at the top) solution of each sample was transferred for lysoGb3
analysis. The 200 μL of the bottom (chloroform) phase solution of
each sample was transferred to another plate and then dried under ni-
trogen. Before analysis for Gb3, the samples were reconstituted with
200 μL of DMSO/MeOH in 2:1 (v/v).
2.3.2. Liquid chromatography for lysoGb3 and Gb3 analysis
We used theWaters Alliance 2795XE HPLC system to perform step-
wise gradient elution. The ﬂow rate was 0.3 mL/min in lysoGb3 or Gb3
experiment. For lysoGb3 analysis, elution was started with 70% mobile
phase A (1%ACN/0.1% FA inwater) and 30%mobile phase B (puremeth-
anol) for 0.5 min, followed by a linear gradient to 10% A and 90% B in
1.5 min. Then, 100%Bwas held for 2.5 to 2.8 min, followed by equilibra-
tion with the starting conditions after 2.9 min. The total run time was
4.2 min. For Gb3 analysis, elution was started with 20% mobile phase
C (0.1 mM ammonia acetate in water and methanol 1:1) and 80% mo-
bile phase D (0.1 mM ammonium acetate in methanol), then achieved
by a linear gradient from 100% D in 2.0 min, followed by the startingTable 1
Characteristics and numbers of all the individuals enrolled in this study.
Male
Mutation 0–19a 20–39 40–59 ≧
IVS4 + 919GNA mutation 96b 9 20 1
Classical mutation
c.394GNA (p.G132R) 1
c.612GNA (p.W204X) 1
c.1034CNG (p.S345X) 1
c.1081GNC (p.G361X) 1
c.1194delA (p.E398DfsX6) 2 1
Healthy control 26 12 13 1
a The age (years) distribution for each gender.
b Total numbers enrolled in each category.conditions of 20% mobile phase C and 80% mobile phase D until equili-
bration. The total run time was 3 min.
2.3.3. Mass spectrometry of lysoGb3 and Gb3
Tandem mass spectrometry detection of lysoGb3 and Gb3 was
performed in positive ionmode (ES+) on a triple quadruplemass spec-
trometer (Quattro Ultima,Waters, Milford, MA) with NeoLynx software
version 4.1. A multiple reaction monitoring (MRM) mode was used for
the measurement of lysoGb3 and Gb3 with details displayed in
Table 2. The analyzing methods were modiﬁed from the protocol pro-
vided by Shire Human Genetic Therapies.
2.3.4. Quantiﬁcation of lysoGb3 and Gb3
For plasma lysoGb3, the total ion current (TIC) was taken as the sum
of lysoGb3 and lyso CDH (IS). LysoGb3 calibrators were measured at
concentrations of 0, 2.5, 5, 50, 100, 200, 300, and 500 nM, and lyso
CDH level corresponded to a constant 100 nM in each sample and cali-
brate. For plasma Gb3, the TIC was taken as the sum of ten speciﬁc
isoforms, C16:0, C17:0 = IS, C18:0, C20:0, C22:1, C22:0, C22:0-OH,
C24:1, C24:0, C24:OH, and C26:0. Gb3. Calibrators were measured at
concentrations of 0, 1.25, 2.5, 5, 10, 15, 20, and 25 μg/mL and the
C17:0-Gb3 IS level corresponded to a constant 5 μg/mL in each sample
and calibrated.
2.4. Method validation
In lysoGb3 analysis, we used low (5 nM) and high (100 nM)
lysoGb3-spiked plasma as quality controls to validate the precision of
the MS/MS experiment. In Gb3 analysis, we used low (2.5 μg/mL) and
high (10 μg/mL) Gb3-spiked plasma as quality controls. The coefﬁcients
of variation from 15 inter-day experiments were 10.2% for low controls
and 7.4% for high controls in lysoGb3 validation, and 10.1% for low con-
trols and 12.1% for high controls in Gb3 validation. The detection limits
which were deﬁned as 3 times of the standard deviation of the ﬁfteen
blank concentrations were 1.0 nM for lysoGb3 and 0.2 μg/mL for Gb3
analysis.
2.5. Statistical methods
Statistical analyses were performed using SAS 9.3. Results are
expressed as median (line) and range. Differences between groups
were assessed by the Mann–Whitney U-test. Multiple regression was
used to determine the association between lysoGb3 as a continuous var-
iable and adjusted for age, gender, and presence of cardiac symptoms.
Square lysoGb3 was used to ﬁt normal residue in multiple regression
analysis.
3. Results
In the ﬁrst part of this study, all Fabry male patients, including 3
asymptomatic infants carrying classical mutations, showed signiﬁcantFemale Total
60 0–19 20–39 40–59 ≧60
2 14 69 28 8 256
1 1 3
4 1 6
1 2
1 2
2 2 7
0 26 10 15 12 124
Table 2
MRM parameter table of lysoGb3 and Gb3.
Compound Parent m/z Product m/z Collision energy Tube lens
Lyso-CDH (IS) 624.3 282.3 28 131
Lyso-Gb3 786.4 282.2 30 167
C16:0-Gb3 1046.8 884.7 56 238
C17:0-Gb3 (IS) 1060.7 898.6 56 238
C18:0-Gb3 1074.8 912.7 57 240
C20:0-Gb3 1102.8 940.7 57 240
C22:1-Gb3 1128.8 966.7 58 240
C22:0-Gb3 1130.8 968.7 58 240
C22:0-OH-Gb3 1146.8 984.7 58 240
C24:1-Gb3 1156.8 994.7 58 240
C24:0-Gb3 1158.8 996.7 58 240
C24:0-OH-Gb3 1174.8 1012.7 58 240
C26:0-Gb3 1186.8 1024.7 58 240
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2.7 μg/mL) compared to the normal male control (lysoGb3: 0.3 ±
0.3 nM, p b 0.01; and Gb3: 2.2 ± 0.7 μg/mL, p b 0.01) (Figs. 1 and 2).
Fabry female patients with classical mutations had lower lysoGb3 levels
(15.4 ± 8.9 nM) than the males; however, all could be easily distin-
guished from normal female controls (0.4 ± 0.2 nM, p b 0.01) by
lysoGb3 levels (Fig. 2), but not Gb3 levels (Fig. 1). For plasma Gb3, a
large proportion of males and females with the IVS4 + 919GNA muta-
tion were below the maximal level of the normal control group (male:
3.2 μg/mL; female: 2.8 μg/mL), even for the symptomatic patients
with the IVS4 + 919GNA mutation. Although the participants with the
IVS4 + 919GNAmutation hadmuch lower lysoGb3 levels than the clas-
sical Fabry patients, all the adult males could be distinguished clearly by
elevated plasma lysoGb3 levels from the male control group (Fig. 2).
According to the second part of this study, all the adult males (symp-
tomatic males: 8.7 ± 3.5 nM, asymptomatic males: 5.8 ± 1.8 nM,
p b 0.01) and symptomatic females (3.0 ± 0.6 nM) could also be dis-
tinguished from the normal male (p b 0.01) and female controls
(Fig. 3). For asymptomatic females, although this group had signiﬁcant-
ly higher lysoGb3 levels (1.5 ± 0.7 nM, p b 0.01) than those from the
normal female control group, around 19% of the adult females had plas-
ma lysoGb3 level below the maximal level (1.1 nM) of the normal con-
trol. Furthermore, to evaluate the impact of disease severity in Fabry
subjects with the IVS4 + 919GNA mutation, multiple regression analy-
sis was performed to determine the association between lysoGb3 levels
and adjusted age, gender, and presence of cardiac symptoms. Even tak-
ing into consideration the impact of age and gender, a positive correla-
tion was clearly demonstrated between plasma lysoGb3 and LVMIFig. 1. Concentration distribution of plasmaGb3 in Fabry subjects and healthy controls. Nmeans
Classical group indicates subjectswith classical Fabrymutation,while IVS4 group is subjectswit
the horizontal line, while the range of plasma Gb3 in each group is shown in bracket.(p b 0.01) for the subjects who were older than 20 years of age with
the IVS4 + 919GNA mutation (Fig. 4).
In the third part of this study, the sample size was enlarged to 256
individuals carrying the IVS4 + 919GNA mutation plus 124 healthy
subjects as the normal control group from newborn to eighty years
of age (Fig. 5). Approximately 70% of the male and 45% of the female
newborns with the IVS4 + 919GNA mutation already had an elevated
lysoGb3 level. Furthermore, the lysoGb3 levels increased gradually
as the age of the subjects increased (p b 0.01). The rate of disease
onset also increased with the elevation of lysoGb3 levels in these indi-
viduals carrying IVS4 + 919GNA mutation.
4. Discussion
In this study, we conﬁrmed that plasma lysoGb3 was a useful bio-
marker for the cardiac variant Fabry disease caused by the IVS4 +
919GNA mutation. All the adult males and symptomatic females with
the IVS4 + 919GNAmutation could be distinguished from normal con-
trols by an elevated plasma lysoGb3 level, but not the plasma Gb3 level.
Moreover, 19% of the adult Fabry females did not have elevated plasma
lysoGb3 levels, and they did not present hypertrophic cardiomyopathy.
Because heterozygous females exhibit awide spectrumof disease sever-
ity ranging from asymptomatic to presentation with classic manifesta-
tions of this disease, this ﬁnding suggests that the plasma lysoGb3
level may identify the high-risk Fabry females who are likely to develop
hypertrophic cardiomyopathy in the future. However, a recent study re-
vealed that a subset of Fabry disease patients with the M296I mutation
did not show any increase in plasma lyso-Gb3 levels, although these
patients exhibited signiﬁcantly clinical manifestations [36]. Extrapolat-
ing these data, it might be possible that some female patients with
IVS4 + 919GNAmutation have already developed hypertrophic cardio-
myopathy, and still have normal serum lysoGb3 levels and cannot be
identiﬁed by the analysis of serum lysoGb3. Since more than one hun-
dred adult Fabry females with this mutation have been evaluated in
this study,we found that lysoGb3 levelsmight still be reliable to identify
most of the high-risk females, if not all with IVS4 + 919GNAmutations.
Furthermore, a positive correlation was found between the increase
in lysoGb3 levels and the increase in the LVMI in either male or female
individuals. We found that subjects with higher lysoGb3 levels might
have a higher tendency of hypertrophic cardiomyopathy. In this study,
all the Fabry male adults who had plasma lysoGb3 higher than 9 nM
and all the female adults who had plasma lysoGb3 higher than 3 nM
had developed hypertrophic cardiomyopathy. Romback et al. had
reported that all male and adult female patients with classical Fabrytotal numbers of evaluated subjects in each group. Control group indicates healthy adults.
h the IVS4 + 919GNAmutation. Themedian of plasmaGb3 in each group is represented by
Fig. 2. Concentration distribution of plasma lysoGb3 in Fabry subjects and healthy controls. N means total numbers of evaluated subjects in each group. Control group indicates healthy
adults. Classical indicates subjects with classical Fabrymutation, while IVS4 is subjects with the IVS4 + 919GNAmutation. Themedian of plasma lysoGb3 in each group is represented by
the horizontal line, while the range is shown in bracket.
118 H.-C. Liao et al. / Clinica Chimica Acta 426 (2013) 114–120disease could be discerned by an elevated plasma lysoGb3, and plasma
lysoGb3 level was related to left ventricular mass and disease severity
[24]. However, we could not clearly distinguish asymptomatic and
symptomatic individuals for either males or females only based on the
plasma lysoGb3 level. Furthermore, these correlations of lysoGb3 and
organ manifestations (cardiac hypertrophy) among the individuals
with IVS4 + 919GNA mutation should be interpreted with care. In
this study,male patients usually have a higher lysoGb3 level than the fe-
male patients. In addition, many asymptomatic males have a much
higher lysoGb3 level than symptomatic females. The reason for this in-
consistence between males and females still remained unanswered.
One possible explanation would be that lysoGb3 is not the only patho-
genic factor in the development of hypertrophic cardiomyopathy.
Other modifying factors might also be involved in the development of
cardiac variant Fabry disease.
Another noteworthyﬁnding in this studywas that a large proportion
of newborns (70% males and 45% females) who carried the IVS4 +
919GNA mutation already had elevated plasma lysoGb3 levels during
their neonatal period. Furthermore, the lysoGb3 levels gradually in-
creased with age of the subjects and the disease onset rate also in-
creased with the elevation of lysoGb3 levels. In Fabry patients older
than 20 years of age, all male adults and 81% of the female adults withFig. 3. Difference of plasma lysoGb3 level between subjects with IVS4 + 919GNA mutation an
(Asym, hollowed circle) and symptomatic (Sym, solid triangle) adult males and females with
N means total numbers of evaluated subjects in each group. (*p b 0.01).this mutation already showed elevation in plasma lysoGb3 levels. Hyper-
trophic cardiomyopathy started to appear when these patients were
older than 40 years old. This ﬁnding indicates that the development of
hypertrophic cardiomyopathy may require a long and insidious course
after the accumulation of lysoGb3 or its related sphingolipids. Previous
studies have suggested that lysoGb3 could enhance toxicity of the viper
venom verotoxin 2, inhibit the enzyme activity of α-galactosidase and
promote the release of secondary mediators such as TGF-β1 and CD74
[37]. Therefore, we believe that lysoGb3 and its related sphingolipids
(Gb3, etc.) could potentially trigger a cascade of events causing cellular
dysfunction and chronic inﬂammatory changes, such as compromised
energy metabolism [38,39], small vessel injury [40], K(Ca)3.1 channel
dysfunction in endothelial cells [41], oxidative stress [42], impaired
autophagosome maturation, etc., which could subsequently lead to hy-
pertrophic cardiomyopathy. Recently, several studies have revealed that
tissue Doppler strain imaging can provide a preclinical diagnosis of
Fabry cardiomyopathy [43,44]. Therefore, we suggest that individuals
who have elevated lysoGb3 levels should be followed up closely with
more sensitive imaging technologies to detect early cardiac involvement
and the early signs of cardiomyopathy. ERTmight be a goodoption topre-
vent irreversible cardiac damage. However, since the efﬁcacy of ERT in
cardiomyopathy of Fabry disease has not reached a universal agreement,d healthy controls. The mean levels of plasma lysoGb3 (horizontal line) in asymptomatic
IVS4 + 919GNA mutation were signiﬁcantly higher than that of healthy normal control.
Fig. 4.Positive correlation of plasma lysoGb3 and left ventricularmass index (LVMI, g/m2.7) inmales and female adultswith the IVS4 + 919GNAmutation.Multiple regression analysiswas
used to determine the association between lysoGb3 and LVMI considering age and gender (β = 0.007, p b 0.01).
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evaluate the efﬁcacy of early ERT in these patients.
Because a large portion of infantswith the IVS4 + 919GNAmutation
already had elevated lysoGb3 levels at birth, this means that Gb3 (or/
and lysoGb3)might start to accumulate long before signiﬁcantly patho-
genic changes of cardiac tissue occur for this type of late-onset Fabry pa-
tients. Considering the high cost of ERT for Fabry disease, it is impossible
to start ERT just depending on the elevation of lysoGb3 levels in these
asymptomatic individuals. Therefore, the crucial issue regarding the
time to start ERT in these asymptomatic individuals carrying the
IVS4 + 919GNA mutation in order to prevent cardiomyopathy still re-
mains unanswered. Therefore, it is necessary to conductmore investiga-
tions and gather more data from these IVS4 + 919GNA patients to
answer these questions. Recently, usingmetabolomics approaches, sev-
eral lysoGb3 related analogs were found in plasma and urine of Fabry
patients [45–48]. Further studies proved that some lysoGb3 analogs
might more speciﬁcally reﬂect the clinical manifestations and progres-
sion of the disease and also correlatedwell with the response of enzyme
replacement therapy. We thus believe that it will be important to ana-
lyze lysoGb3 related analogs in plasma and urine of our patients with
IVS4 + 919GNA mutations.
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